Baseline demographic and disease characteristics of biologic-naive patients from PSUMMIT 1 and PSUMMIT 2.
| Improved | Worsened | Unchanged | Total | |
|---|---|---|---|---|
| Patients, n | 158 | 21 | 412 | 591 |
| Female | 58 (36.7) | 9 (42.9) | 198 (48.1) | 265 (44.8) |
| Age, yrs | 45.2 ± 12.0 | 43.6 ± 13.5 | 48.3 ± 11.7 | 47.3 ± 11.9 |
| BMI, kg/m2 | 29.2 ± 6.1 | 29.5 ± 6.4 | 30.7 ± 7.1 | 30.2 ± 6.9 |
| PsA duration, yrs | 6.4 ± 7.4 | 6.7 ± 8.3 | 6.7 ± 7.6 | 6.7 ± 7.6 |
| PsA subtypes | ||||
| DIP joint arthritis | 12 (7.6) | 3 (14.3) | 50 (12.1) | 65 (11.0) |
| Arthritis mutilans | 2 (1.3) | 0 | 2 (0.5) | 4 (0.7) |
| Asymmetric peripheral arthritis | 31 (19.6) | 3 (14.3) | 91 (22.1) | 125 (21.2) |
| Polyarticular arthritis with no rheumatoid nodules | 60 (38.0) | 9 (42.9) | 149 (36.2) | 218 (36.9) |
| Spondylitis with peripheral arthritis | 53 (33.5) | 6 (28.6) | 120 (29.1) | 179 (30.3) |
| MTX use | 85 (53.8) | 7 (33.3) | 205 (49.8) | 297 (50.3) |
| HAQ-DI | 1.1 ± 0.6 | 1.1 ± 0.6 | 1.3 ± 0.6 | 1.2 ± 0.6 |
| SF-36 PCS | 32.5 ± 8.6 | 31.9 ± 8.5 | 30.9 ± 8.5 | 31.4 ± 8.5 |
| SF-36 MCS | 44.3 ± 11.0 | 45.6 ± 11.6 | 42.7 ± 11.6 | 43.3 ± 11.5 |
Data presented as n (%) or mean ± SD unless otherwise noted. BMI: body mass index; DIP: distal interphalangeal; HAQ-DI: Health Assessment Questionnaire–Disability Index; MTX: methotrexate; PsA: psoriatic arthritis; SF-36 PCS/MCS: Medical Outcomes Study Short Form-36 Health Survey physical/mental component summary.